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Abstract
Purpose Cardiac dysfunction, particularly QT interval
prolongation, has been observed with tyrosine kinase
inhibitors approved to treat chronic myeloid leukemia. This
study examines the effects of ponatinib on cardiac repo-
larization in patients with refractory hematological malig-
nancies enrolled in a phase 1 trial.
Methods Electrocardiograms (ECGs) were collected at 3
dose levels (30, 45, and 60 mg) at 6 time points. Electro-
cardiographic parameters, including QTc interval, were
measured, and 11 morphological analyses were conducted.
Central tendency analyses of ECG parameters were per-
formed using time-point and time-averaged approaches.
All patients with at least 2 baseline ECGs and 1 on-treat-
ment ECG were included in the analyses. Patients with
paired ECGs and plasma samples were included in the
pharmacokinetic/pharmacodynamic analysis to examine
the relationship between ponatinib plasma concentration
and change from baseline in QT intervals.
Results Thirty-nine patients at the 30-, 45-, and 60-mg
dose levels were included in the central tendency and
morphological analyses. There was no significant effect on
cardiac repolarization, as evidenced by non-clinically sig-
nificant mean QTcF changes from baseline of -10.9, -3.6,
and -5.0 ms for the 30-, 45-, and 60-mg dose levels,
respectively. The morphological analysis revealed 2
patients with atrial fibrillation and 2 with T wave inversion.
Seventy-five patients were included in the pharmacoki-
netic/pharmacodynamic analysis across all dose levels. The
slope of the relationship for QTcF versus plasma ponatinib
Data from this study have previously been presented at the 2011
American Society of Hematology Annual Meeting, December 10–13,
2011, San Diego CA, USA. Blood. 2011; 118: Abstract 4441.
D. Sonnichsen  D. J. Dorer  C. D. Turner  F. G. Haluska (&)
ARIAD Pharmaceuticals, Inc., 26 Landsdowne St.,
Cambridge, MA 02139, USA
e-mail: frank.haluska@ariad.com
D. Sonnichsen
Sonnichsen Pharmaceutical Associates, Collegeville, PA, USA
J. Cortes  H. M. Kantarjian
Division of Cancer Medicine, Department of Leukemia,
The University of Texas M.D. Anderson Cancer Center,
Houston, TX, USA
M. Talpaz
Division of Hematology and Oncology, Department of Internal
Medicine, University of Michigan Comprehensive Cancer
Center, Ann Arbor, MI, USA
M. W. Deininger
Center for Hematologic Malignancies, Knight Cancer Institute,
Oregon Health & Science University, Portland, OR, USA
Present Address:
M. W. Deininger
Division of Hematology and Hematologic Malignancies,
Department of Oncological Sciences, Huntsman Cancer
Institute, University of Utah, 2000 Circle of Hope,
Salt Lake City, UT 84112, USA
N. P. Shah
Department of Hematology/Oncology, University of California
San Francisco, San Francisco, CA, USA
D. Bixby
Division of Hematology and Oncology, University of Michigan
Comprehensive Cancer Center, Ann Arbor, MI, USA
M. J. Mauro
Data Safety Monitoring Committee, Center for Hematologic
Malignancies, Knight Cancer Institute, Oregon Health and
Science University, Portland, OR, USA
123
Cancer Chemother Pharmacol (2013) 71:1599–1607
DOI 10.1007/s00280-013-2160-7
concentration was not positive (-0.0171), indicating no
exposure–effect relationship.
Conclusions Ponatinib is associated with a low risk of
QTc prolongation in patients with refractory hematological
malignancies.
Keywords Ponatinib  BCR-ABL  Chronic myeloid
leukemia  Philadelphia chromosome  Drug safety 
Electrocardiography
Introduction
Ponatinib (AP24534) is a novel, synthetic, orally admin-
istered, multi-targeted tyrosine kinase inhibitor (TKI) and a
potent pan–BCR-ABL inhibitor [1–3]. The product of a
computational and structure-based approach to the design
of a small-molecule TKI, ponatinib binds with high affinity
to the active site of BCR-ABL and renders binding less
susceptible to any single amino acid substitution [1]. Po-
natinib contains an unique carbon–carbon triple bond
linkage that avoids the steric hindrance to other drugs
caused by the bulky isoleucine residue at position 315 in
the T315I mutant.
Based on the results in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive
acute lymphoblastic leukemia (Ph? ALL) in phase 1 test-
ing and phase 2 clinical trials [4, 5], ponatinib (45 mg once
daily) has been approved in the United States for the
treatment of patients with CML and Ph? ALL that is
resistant or intolerant to prior TKI therapy [6].
Cardiac dysfunction has been noted with other TKIs
approved for the treatment of patients with CML. For
example, the imatinib prescribing information includes a
warning regarding congestive heart failure and left ven-
tricular dysfunction [7]. The nilotinib prescribing infor-
mation includes ‘‘QT prolongation’’ as a boxed warning
[8], and the dasatinib prescribing information carries ‘‘QT
prolongation’’ as a precaution [9]. During phase 1 testing of
ponatinib, treatment-related QTc prolongation was
observed in 4 % of patients [4].
The QT interval is a measure of the duration of the
electrical depolarization and repolarization of the ventri-
cles of the heart and serves as a surrogate marker for the
risk of torsades de pointes, which can lead to sudden
death. The International Conference on Harmonisation
E14 guidelines [10] outline requirements for studies of the
effects of drugs on the QT interval. Specifically, the ideal
QT study would include a placebo and control drug along
with evaluation of a supratherapeutic dose. However, it is
not often possible to implement such a study design with
cancer patients, particularly the use of a placebo and
positive controls.
The cardiac safety of ponatinib was initially investigated
in an in vitro assay conducted in human embryonic kidney
cells stably expressing the hERG potassium channel. In this
study, 5 ponatinib doses were compared with the positive
control cisapride (unpublished data, ARIAD Pharmaceuti-
cals, Cambridge, MA). This preclinical study revealed that
ponatinib inhibits hERG current, which is implicated in the
prolongation of cardiac repolarization, at concentrations
above 1 lM, which is substantially in excess of the steady-
state ponatinib maximal concentrations (Cmax) observed in
patients treated at the clinical dose of 45 mg orally once
daily (geometric mean, 77.4 ng/mL or 0.145 lM) [4]. The
cardiac safety of ponatinib was also investigated in vivo in
4 conscious telemetered dogs (unpublished data, ARIAD
Pharmaceuticals, Cambridge, MA). In this study, dogs
received vehicle and 3 doses of ponatinib (2, 5, and 10 mg/
kg) administered 1 week apart; electrocardiographic
(ECG), heart rate, and arterial pressure measurements were
taken to assess the effects of ponatinib on cardiovascular
parameters. This in vivo study showed that oral adminis-
tration of single doses of ponatinib up to 10 mg/kg was not
associated with biologically relevant effects on cardiac or
circulatory function.
This report is a safety analysis of the phase 1 trial
focused on the potential effects of ponatinib on cardiac
repolarization in patients with refractory hematological
malignancies.
Methods
Study design
The design of this phase 1 trial has been previously
described [4]. There were 7 dose levels, with doses ranging
from 2 to 60 mg. The primary objective was to determine
the maximal tolerated dose, and secondary objectives
included safety/tolerability, anti-leukemia activity, and
pharmacokinetics (PK)/pharmacodynamics (PD). An
additional secondary end point was introduced through a
protocol amendment allowing analysis of ECG parameters
including the QTc interval, which was primarily assessed
using the Fridericia-corrected method (QTcF). The proto-
col amendment, under which all patients included in the
central tendency and outlier analyses were evaluated,
required baseline QTc to be less than 450 ms and
I. W. Flinn
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prohibited concomitant use of medications known to pro-
long the QTc interval.
All patients provided signed informed consent. The
protocol, amendments, and consent forms were approved
by the institutional review board at each center. The study
was conducted in accordance with the Guidelines for Good
Clinical Practice and the Declaration of Helsinki.
Analysis population
All patients in the 3 dose groups (30, 45, and 60 mg) with
at least 2 available baseline ECGs and 1 on-treatment ECG
were included in the central tendency and outlier analyses
of ECG parameters (39 of 57 patients at these dose levels
met these criteria). All patients across all dose levels with
paired ECG and plasma concentrations for ponatinib were
included in the PK/PD analysis (75 of 81 patients met these
criteria).
ECG evaluation
Resting 12-lead ECGs were collected across the 3 dose
levels (30, 45, and 60 mg) and at 6 time points: baseline (day
1, in triplicate), predose; day 15, predose (single); day 29
(cycle 2/day 1), predose (in triplicate); day 29, 2 h post-dose
(in triplicate); day 29, 4 h post-dose (in triplicate); and day
29, 6 h post-dose (in triplicate). Patients were supine and at
rest during ECG recording, which was performed from all 12
leads simultaneously for 10 s. Electrocardiograms were
recorded using GE MAC1200 ECG recorders (version 6.1)
at each study site and transmitted to a central laboratory for
analysis conducted by a cardiologist.
Six cardiac interval durations were measured: heart rate,
PR interval, QRS interval, QT interval, QTcF, and Bazett-
corrected QT (QTcB). In addition, 11 morphological
analyses were conducted to identify the onset of new
morphological abnormalities: atrial fibrillation and atrial
flutter, second- and third-degree heart block, complete left
and right bundle branch block, ST-segment change (ele-
vation and depression separately), wave abnormalities
(negative T waves only), myocardial infarction pattern, and
abnormal U waves.
Statistical analysis of ECG parameters: central
tendency analysis and outlier analysis
The central tendency analysis of all ECG interval param-
eters, defined as a change from baseline to post-treatment
time points (except for cycle 1/day 15, predose), was per-
formed using 2 approaches: time point and time averaged.
For the time-point analysis, 3 ECGs were to be collected at
each time point (baseline and 4 post-treatment visits);
however, post-dose time points with only 2 ECGs were
included in this analysis. The data from the 2 or 3 ECGs
were averaged to provide a single set of ECG intervals for
each time point. Data were summarized using descriptive
statistics. Changes from baseline to 4 post-treatment time
points were described with data-based (not model-based)
2-sided 90 % CI statistics. For QTc measurements, the
QTcF method was the primary measurement; QTcB was
considered secondary, provided for historical purposes
only. For the time-averaged analysis, baseline time points
were averaged and the value obtained was subtracted from
the mean of all combined 4 post-treatment ECG time
points.
Outlier or categorical analysis was also performed to
identify patients who experienced a significant effect on
any ECG interval parameter (heart rate, PR interval, QRS
interval, QT interval, QTcF, and QTcB) that would not be
revealed by the central tendency analysis and should be
considered exploratory in nature. This analysis used a time-
averaged approach that compared the baseline ECG inter-
val value with all post-treatment ECG time points, and
then, the value that represented the greatest positive change
from baseline was chosen to determine whether each
patient fell into the outlier criterion. For heart rate, both the
largest negative and positive value compared with baseline
was chosen.
Pharmacokinetic/pharmacodynamic evaluations
Plasma samples were collected concomitantly with ECG
assessments. A linear mixed-effects modeling approach
was used to quantify the relationship between the plasma
concentration of ponatinib and the change from baseline in
QT intervals. This model was used to estimate the popu-
lation slope and the standard error of the slope of the
relationship between the change from baseline in QTc
intervals and plasma concentrations of ponatinib. As this
model is meant solely to determine the relationship of QTc
change with the degree of change in exposure, the time
points are not relevant; therefore, all plasma concentration
and time point QTc pairs were used irrespective of the time
point and the dose group from which such pairs were taken.
A linear relationship was declared if the P value of the
slope was less than 0.05.
Results
Patient characteristics
Thirty-nine patients who received 30–60 mg of ponatinib
once daily were included in the primary cardiac safety
analysis. The demographic characteristics are summarized
in Table 1. In the phase 1 clinical study, geometric mean
Cancer Chemother Pharmacol (2013) 71:1599–1607 1601
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(range) values of Cmax for ponatinib measured at steady
state (day 29) were 64.6 (35.9–94.8) ng/mL at 30 mg, 77.4
(34.3–179) ng/mL at 45 mg, and 97.5 (54.3–231) ng/mL at
60 mg [4]. As of March 23, 2012, 7 patients had experi-
enced 1 or more treatment-related adverse events in the
cardiac disorders MedDRA system organ class (2 left
ventricular dysfunction, 2 tricuspid valve incompetence,
and 1 each aortic valve sclerosis, atrial fibrillation, cardiac
failure congestive, cardiomegaly, cardiomyopathy, left
ventricular hypertrophy, palpitations, and pericardial effu-
sion). Most of these events were grade 1 or 2 in severity.
Three patients experienced treatment-related adverse
events of QT prolongation (grade 2 or 3).
Time-averaged central tendency analysis
The mean changes from baseline in heart rate across po-
natinib dose levels (?3.5 bpm, -3.3 bpm, and ?1.0 bpm
for 30-, 45-, and 60-mg dose levels, respectively) were not
clinically significant; there were 2 tachycardia outliers (1 at
the 45-mg dose level and 1 at the 60-mg dose level) and no
bradycardia outliers (Table 2). The effects on atrioven-
tricular conduction, as measured by mean change from
baseline in the PR interval (-0.4, -3.6, and -0.7 ms for
the 30-, 45-, and 60-mg dose levels, respectively), were not
clinically significant, and there were no outliers (Table 2).
The time-averaged mean change from baseline across the
ponatinib 30-, 45-, and 60-mg dose levels for QRS interval
duration showed a change of -0.8, ?1.3, and ?3.6 ms
(Table 2). These changes are unlikely to be clinically rel-
evant, and there were no outliers. A small effect on QRS
interval cannot be ruled out at 60 mg due to the small
sample size (12 patients); however, the recommended dose
of ponatinib is 45 mg. The time-point analysis showed no
signal of any effect. There was no significant effect on
cardiac repolarization, as demonstrated by the non-clini-
cally significant change in QTcF across the doses exam-
ined. The mean QTcF changes from baseline were -10.9,
-3.6, and -5.0 ms for the 30-, 45-, and 60-mg dose levels,
respectively.
The findings from the outlier analysis of absolute QTcF
duration identified few patients experiencing QTcF pro-
longation (Table 2). One patient at the 45-mg dose level
(5 %) had a QTcF [500 ms; 1 patient at the 60-mg dose
level (8 %) had a change in QTcF [60 ms from baseline;
and 3 patients at the 45-mg dose level (14 %) had a 30- to
60-ms change in QTcF from baseline (Table 2). The
patient at the 45-mg dose level with a QTcF[500 ms had a
Cmax of 57.6 ng/mL, which was below the geometric mean
Cmax at the 45-mg dose level (77.4 ng/mL) [4]. This patient
was receiving concomitant Darvocet (acetaminophen and
propoxyphene), a medication known to prolong the QTc
interval.
Morphological analysis
Atrial fibrillation and T wave inversion were observed in 2
chronic-phase CML patients each (Table 2). Three of these
4 patients had a history of cardiovascular disease (e.g.,
stroke, hypertension, intermittent sinus bradycardia, and
palpitations), suggesting that these morphological abnor-
malities may reflect the patient population being studied
rather than representing an effect of the study medication.
Given their age (median, 49 years) and ECOG performance
status, the patients in this study are representative of the
patient population that will be treated with ponatinib in the
clinic. The fourth patient was taking concomitant moxi-
floxacin, a medication known to be associated with cardiac
arrhythmias (in violation of the study protocol) [11].
Table 1 Demographic characteristics of patients included in the
cardiac analysis
Characteristics Ponatinib 30–60 mg
(N = 39)
Age
Median (range), years 49.0 (27–85)
C65 years, n (%) 8 (20.5)
Gender, n (%)
Male 26 (66.7)
Female 13 (33.3)
ECOG performance status, n (%)
0 20 (51.3)
1 15 (38.5)
2 4 (10.3)
Median time (range) from diagnosis to
treatment, years
4.8 (0.6, 23.5)
Diagnosis, n (%)
Chronic-phase CML 25 (64.1)
Accelerated-phase CML 1 (2.6)
Blast-phase CML 4 (10.3)
Ph? ALL 4 (10.3)
AML 5 (12.8)
Prior number of TKIs, n (%)
0 0 (0.0)
1 3 (7.7)
2 12 (30.8)
C3 19 (48.7)
Missing 5 (12.8)
AML acute myeloid leukemia, CML chronic myeloid leukemia,
ECOG Eastern Cooperative Oncology Group, Ph? ALL Philadelphia
chromosome–positive acute lymphoblastic leukemia, TKIs tyrosine
kinase inhibitors
1602 Cancer Chemother Pharmacol (2013) 71:1599–1607
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Time-point central tendency analysis
Time-point analysis of 6 ECG parameters revealed no
effect of ponatinib across 4 on-treatment time points
(Fig. 1). These time points were selected based on the
steady-state Cmax of ponatinib; therefore, these findings
indicate that even at the highest concentrations, ponatinib
had no significant effect on the ECG parameters analyzed
(Fig. 1).
Pharmacokinetic/pharmacodynamic analysis
Sixty-nine of the total 81 patients enrolled in this phase 1
study had paired baseline/post-baseline time-matched PK-
ECG data and were included in the concentration delta QTc
mixed model analysis. The slope of the relationship for
QTcF versus plasma ponatinib concentration was not
positive (Table 3; Fig. 2), indicating no exposure–effect
relationship. The estimated QTcF mean change at Cmax
was -6.4 ms at the 60-mg dose level and -6.2 at the
45-mg dose level (Table 4).
Discussion
This analysis of QTc intervals in patients with refractory
hematological malignancies who received daily doses of
30, 45, or 60 mg of ponatinib in a phase 1 clinical trial
revealed no significant effect of ponatinib on cardiac
repolarization. The recommended dose of ponatinib is
45 mg. Initial characterization of cardiac safety, including
QT prolongation, was previously described across all 81
patients included in this phase 1 trial [4]. Although dose-
limiting toxicities identified in phase 1 did not include
cardiovascular findings, among the adverse events reported
in the trial (n = 81), 3 patients (4 %) experienced treat-
ment-related QT prolongation: 1 patient each at the 2-, 4-,
and 45-mg dose levels. Of these 3 patients, 2 (3 %)
experienced grade 3 treatment-related QT prolongation (at
the 4- and 45-mg dose levels). All 3 patients had low
steady-state Cmax (4.5–57.6 ng/mL), suggesting that QT
prolongation was not due to increased ponatinib exposure.
Two of the 3 patients were enrolled before protocol
amendment, and all 3 patients were found to have pro-
longation of QTc at baseline or to have received concom-
itant medications known to be associated with QTc
prolongation. There were no clinical consequences of the
ECG findings in these patients.
The results of this cardiac analysis suggest that ponati-
nib is associated with a low risk of QTc prolongation.
Other targeted agents approved for the treatment of CML
have been found to be associated with cardiac toxicities [7–
9]. Imatinib has been associated with left ventricular dys-
function and heart failure, particularly in patients with
comorbidities and risk factors [7, 12]. In the phase 3
International Randomized Study of Interferon and STI571
(IRIS) in 1,106 patients with newly diagnosed Ph? CML,
severe cardiac failure and left ventricular dysfunction were
Table 2 Electrocardiographic interval parameters (time-averaged
central tendency analysis), outlier analysis, and morphological
abnormalities, by dose level
Ponatinib
30 mg
(n = 6)
Ponatinib
45 mg
(n = 21)
Ponatinib
60 mg
(n = 12)
Electrocardiographic interval parameters and outlier analysis
Heart rate, mean change from
baseline, bpm
3.5 -3.3 1.0
Heart rate tachycardic outliers,
n (%)
0 (0) 1 (5) 1 (8)
PR interval, mean change from
baseline, ms
-0.4 -3.6 -0.7
PR interval outliers, n (%) 0 (0) 0 (0) 0 (0)
QRS interval, mean change from
baseline, ms
-0.8 1.3 3.6
QRS interval outliers, n (%) 0 (0) 0 (0) 0 (0)
QT interval, mean change from
baseline, ms
-13.4 3.3 -4.6
QTcF, mean change from
baseline, ms
-10.9 -3.6 -5.0
QTcF [500 ms, n (%) 0 (0) 1 (5) 0 (0)
QTcF [60 ms change from
baseline, n (%)
0 (0) 0 (0) 1 (8)
QTcF 30- to 60-ms change from
baseline, n (%)
0 (0) 3 (14) 0 (0)
QTcBa, mean change from
baseline, ms
-9.2 -7.4 -4.9
Morphological abnormalities, n (%)
Atrial fibrillation 1 (17) 0 (0) 1 (8)
T wave inversion 0 (0) 1 (5) 1 (8)
Atrial flutter 0 (0) 0 (0) 0 (0)
Myocardial infarction 0 (0) 0 (0) 0 (0)
Second- or third-degree heart
block
0 (0) 0 (0) 0 (0)
RBBB or LBBB 0 (0) 0 (0) 0 (0)
ST-segment elevation or
depression
0 (0) 0 (0) 0 (0)
Abnormal U waves 0 (0) 0 (0) 0 (0)
bpm beats per minute, ms milliseconds, QTcF Fridericia-corrected
QT, QTcB Bazett-corrected QT, RBBB right bundle branch block,
LBBB left bundle branch block
a The Bazett correction method is often less reliable than the Fri-
dericia correction method; QTcB is provided for historical purposes
only
Cancer Chemother Pharmacol (2013) 71:1599–1607 1603
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Fig. 1 Mean (±90 % CI) change from baseline in electrocardiographic interval parameters for 4 on-treatment time points (time-point central
tendency analysis). CI confidence interval, bpm beats per minute, ms milliseconds, QTcF Fridericia-corrected QT, QTcB Bazett-corrected QT
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observed in 0.7 % of patients taking imatinib compared
with 0.9 % of patients taking interferon alfa plus cytarabine
[7, 13, 14]. The dasatinib prescribing information carries
QT prolongation as a precaution. In a phase 1 trial
(NCT01392703) in 75 healthy subjects, a clear QT pro-
longation effect was not detected [15]. However, this
adverse event emerged in a phase 3 trial conducted in
patients newly diagnosed with CML: QTc intervals
between 450 and 500 ms were observed in 2 % of the
patients taking dasatinib, compared with 4 % of patients
taking imatinib [16]. The nilotinib prescribing information
includes a boxed warning regarding QT prolongation [8].
Results of ECG analyses conducted on about 400 patients
with CML who participated in a phase 1/2 trial
(NCT00109707) showed a significant association between
nilotinib concentration and a change from baseline in
QTcF, indicating a prolongation of the QTc interval asso-
ciated with nilotinib [17–19]. A modest linear correlation
between nilotinib concentration and a change from baseline
in QTcF along with a higher incidence of developing
ischemic heart disease in the nilotinib arms was also found
in the phase 3 trial Evaluating Nilotinib Efficacy and Safety
in Clinical Trials—Newly Diagnosed Patients (ENESTnd)
conducted in patients with newly diagnosed CML [20, 21].
Finally, the effects of bosutinib on cardiac repolarization
were studied in a randomized, crossover, placebo- and
moxifloxacin-controlled study. In the healthy adult subjects
enrolled in this study, therapeutic and supratherapeutic
bosutinib exposures were not associated with QTc pro-
longation [22].
This study had 2 primary limitations. First, the study
was not designed as a true thorough QT study as outlined
by the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use E14 guidelines. However, it is
worthwhile noting that formal thorough QT studies are
difficult, if not impossible, to conduct ethically in this
patient population owing to the requirement for placebo
and positive controls. Second, the number of subjects
enrolled in the study was relatively small, particularly for
dose-level analyses. Unlike the healthy subject QTc anal-
ysis conducted with nilotinib, this study evaluated the
cardiac effects of ponatinib in a patient population with
refractory hematological malignancies, which may increase
confidence that these results are consistent with what will
be seen in clinical practice.
The results of this QTc analysis in CML patients treated
with ponatinib at clinically relevant doses suggest that
ponatinib is associated with a low risk of QTc
prolongation.
Fig. 2 QTcF change from baseline by ponatinib plasma concentra-
tion across 7 dose levels (N = 69). QTcF Fridericia-corrected QT, ms
milliseconds
Table 4 Estimates from linear mixed model QTcF and QTcB
Ponatinib 30 mg
(n = 6)
Ponatinib 45 mg
(n = 21)
Ponatinib 60 mg
(n = 12)
Ponatinib 30–60 mg
(N = 39)
QTc parameter QTcF QTcB QTcF QTcB QTcF QTcB QTcF QTcB
Predicted DQTc at average Cmax, ms -5.5888 -5.6112 -6.2318 -5.9544 -6.4421 -6.0666 -6.1885 -5.9313
One-sided upper 95 % confidence bound
of predicted DQTc, ms
-1.3242 -0.7051 -1.1137 -0.0432 -0.9124 0.3126 -1.1486 -0.1096
QTcF Fridericia-corrected QT, QTcB Bazett-corrected QT, ms milliseconds
Table 3 Change from baseline versus ponatinib plasma
concentration
QTc parameter
QTcF QTcB
Slope of plasma concentration effect on DQTc -0.0171 -0.0091
Standard error of plasma concentration
effect on DQTc
0.0321 0.0358
P value slope of plasma concentration
effect on DQTc
0.5958 0.7997
Overall model fit \0.0001 \0.0001
QTcF Fridericia-corrected QT, QTcB Bazett-corrected QT
Cancer Chemother Pharmacol (2013) 71:1599–1607 1605
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